RAS Mutation Prevalence Among Patients With Metastatic Colorectal Cancer: a Meta-Analysis of Real-World Data

作者：George Kafatos, Daniela Niepel, Kimberley Lowe, Sophie Jenkins-Anderson, Hal Westhead, Tamer Garawin, Zuzana Traugottová, Antonios Bilalis, Edit Molnar, József Tı́már, Erika Tóth, Nikolaos Gouvas, George Papaxoinis, Samuel Murray, Nadia Mokhtar, Hana Vošmiková, Pavel Fabián, Alena Skálová, Piotr Wójcik, Andrzej Tysarowski, Mario Barugel, J. Han van Krieken, Jörg Trojan · 发表于：Biomarkers in Medicine · 年份：2017 · DOI：10.2217/bmm-2016-0358 · 被引用次数：48 · 研究领域：Colorectal Cancer Treatments and Studies、Cancer Genomics and Diagnostics、Lung Cancer Treatments and Mutations

AIM: A confirmed wild-type RAS tumor status is commonly required for prescribing anti-EGFR treatment for metastatic colorectal cancer. This noninterventional, observational research project estimated RAS mutation prevalence from real-world sources. MATERIALS & METHODS: Aggregate RAS mutation data were collected from 12 sources in three regions. Each source was analyzed separately; pooled prevalence estimates were then derived from meta-analyses. RESULTS: The pooled RAS mutation prevalence from 4431 tumor samples tested for RAS mutation status was estimated to be 43.6% (95% CI: 38.8-48.5%); ranging from 33.7% (95% CI: 28.4-39.3%) to 54.1% (95% CI: 51.7-56.5%) between sources. CONCLUSION: The RAS mutation prevalence estimates varied among sources. The reasons for this are not clear and highlight the need for further research.